Event Information:
Date
November 6th to 10th, 2024
Location
Houston, Texas, USA
Related Models
TransCure BioServices at SITC 2024
We are pleased to announce that Dan Georgess, PhD, Chief Scientific Officer, and Philippe Michon, Business Developer, will be attending the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting from November 6-10, 2024, in Houston, Texas.
SITC is a premier event for global leaders in immunotherapy to discuss groundbreaking research and the latest advancements in cancer treatment.
At TransCure BioServices, we provide cutting-edge humanized mouse models that play a vital role in advancing preclinical research in immuno-oncology. Our models, including CD34+ humanized immune system mice, humanized liver mice, and dual humanized models, are essential for the development of innovative cancer immunotherapies.
If you are attending the event, don’t miss the opportunity to meet with Dan and Philippe to explore how our models can accelerate your preclinical studies and support your therapeutic research.
For more information, visit: https://www.sitcancer.org/2024/home
Attending in person for TransCure bioServices:
Dan Georgess, PhD, Chief Scientific Officer
Dan is an innovative scientist with extensive international experience in team leadership, research strategy, and interdisciplinary collaboration. He is dedicated to promoting cross-functional efforts to address complex challenges in therapeutics development. Prior to joining TransCure bioServices, Dan was a Marie Curie Ph.D. fellow at ENS de Lyon (France), Suzan G. Komen postdoctoral fellow at the Johns Hopkins School of Medicine (USA), and assistant professor and leader of the Cancer Invasion and Metastasis Cluster at the Lebanese American University (Lebanon). In these roles, he developed cutting-edge in vivo and ex vivo approaches for hematopoiesis, autoimmunity, and cancer research, and co-authored 15 peer-reviewed publications. Since joining TransCure bioServices in 2022, initially as Project Leader then transitioning to Director of the Alliance Management Team and now CSO, Dan’s consistent focus has been to drive successful preclinical development of cell therapies and biologics for TransCure’s clients.
Attending in person for TransCure bioServices:
Philippe Michon, Business Development
Philippe Michon holds an MBA from H.E.C. Montreal and joined Transcure in 2024. Prior he worked with XenTech, a preclinical oncology CRO focusing on PDX technology, as Head of BD. He’s an experienced and trusted professional with established history of technology software and CRO/Service sales achievements in the R&D Life Sciences arena. 20+ years selling innovative digital solutions including business development and strategic planning activities, as well as providing leadership in the areas of selling, reporting, forecasting, budgeting, pricing, and contract negotiation. A proven team player with good interpersonal, communication and organizational skills with a record of successful dynamism and combined entrepreneurial management.